Cargando…
Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza
BACKGROUND: Danirixin (DNX), a selective and reversible CXC chemokine receptor 2 antagonist, inhibits neutrophil transmigration and activation. This study assessed the safety, tolerability, and clinical effect of DNX with and without oseltamivir (OSV) in adults with acute, uncomplicated influenza. M...
Autores principales: | Roberts, Grace, Chen, Shuguang, Yates, Phillip, Madan, Anuradha, Walker, Jill, Washburn, Michael L, Peat, Andrew J, Soucie, Gary, Kerwin, Edward, Roy-Ghanta, Sumita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476494/ https://www.ncbi.nlm.nih.gov/pubmed/31024969 http://dx.doi.org/10.1093/ofid/ofz072 |
Ejemplares similares
-
Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza
por: Madan, Anuradha, et al.
Publicado: (2019) -
Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials
por: Hayden, Frederick G, et al.
Publicado: (2022) -
Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
por: Holubar, Marisa, et al.
Publicado: (2022) -
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection
por: Lim, Jeremy J, et al.
Publicado: (2021) -
Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study
por: Roy-Ghanta, Sumita, et al.
Publicado: (2014)